CA3006827A1 - Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer - Google Patents
Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer Download PDFInfo
- Publication number
- CA3006827A1 CA3006827A1 CA3006827A CA3006827A CA3006827A1 CA 3006827 A1 CA3006827 A1 CA 3006827A1 CA 3006827 A CA3006827 A CA 3006827A CA 3006827 A CA3006827 A CA 3006827A CA 3006827 A1 CA3006827 A1 CA 3006827A1
- Authority
- CA
- Canada
- Prior art keywords
- aso
- seq
- cancer
- mct4
- linkage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260837P | 2015-11-30 | 2015-11-30 | |
| US62/260,837 | 2015-11-30 | ||
| PCT/CA2016/000296 WO2017091885A1 (en) | 2015-11-30 | 2016-11-30 | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3006827A1 true CA3006827A1 (en) | 2017-06-08 |
Family
ID=58795956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3006827A Pending CA3006827A1 (en) | 2015-11-30 | 2016-11-30 | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10889814B2 (enExample) |
| EP (1) | EP3384028B1 (enExample) |
| JP (1) | JP7039470B2 (enExample) |
| CN (1) | CN108603194A (enExample) |
| AU (1) | AU2016363683B2 (enExample) |
| CA (1) | CA3006827A1 (enExample) |
| ES (1) | ES2893294T3 (enExample) |
| MX (1) | MX2018006527A (enExample) |
| WO (1) | WO2017091885A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017091885A1 (en) | 2015-11-30 | 2017-06-08 | The University Of British Columbia | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
| MX2019001389A (es) | 2019-01-31 | 2020-02-20 | Atso Corp Affairs S A De C V | Oligonucleotidos antisentido de las glutation s transferasa para el tratamiento del cancer. |
| EP3999117A4 (en) * | 2019-07-12 | 2023-07-26 | Duke University | NANOPARTICLE SYSTEMS FOR TARGETED CRISPR/CAS13 DELIVERY AND METHODS OF USE THEREOF |
| CN113197903B (zh) * | 2021-05-08 | 2022-01-07 | 江南大学 | 聚普瑞锌在制备用于治疗去势抵抗性前列腺癌药物中的应用 |
| WO2022250466A1 (ko) * | 2021-05-27 | 2022-12-01 | 사회복지법인 삼성생명공익재단 | 전립선암의 엔잘루타미드 저항성 억제용 약학 조성물 및 엔잘루타미드 저항성을 가지는 전립선암 치료용 약학 조성물 |
| CN113717971B (zh) * | 2021-08-10 | 2025-03-28 | 南通大学 | PGK1靶向siRNA干扰库及其应用 |
| CN114324870A (zh) * | 2021-12-22 | 2022-04-12 | 中国人民解放军空军军医大学 | 靶向髓系细胞乳酸转运信号的肺癌生物标志物和检测试剂盒 |
| CN114246829B (zh) * | 2021-12-31 | 2023-03-24 | 北京大学 | 一种反义核酸药物的包载方法、由该方法制备得到的药物制剂及其在肝癌治疗中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19832763A1 (de) | 1997-07-21 | 1999-03-18 | Schuster Christoph | Kraftfahrzeug mit einem verschließbaren Fahrerraum |
| NZ513757A (en) | 1999-02-26 | 2004-12-24 | Univ British Columbia | Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells |
| US20030059781A1 (en) * | 2000-03-21 | 2003-03-27 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer |
| US6637473B2 (en) | 2000-10-30 | 2003-10-28 | Robodesign International, Inc. | Automated storage and retrieval device and method |
| NZ538841A (en) | 2002-10-02 | 2006-10-27 | Univ British Columbia | Compositions for reducing hsp27 for the treatment of prostate and other cancers |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20050255114A1 (en) * | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| GB2407837B (en) | 2003-11-04 | 2007-07-11 | Corus Uk Ltd | Traffic control barriers |
| US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
| US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| US10570457B2 (en) | 2014-09-26 | 2020-02-25 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| WO2017091885A1 (en) | 2015-11-30 | 2017-06-08 | The University Of British Columbia | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
-
2016
- 2016-11-30 WO PCT/CA2016/000296 patent/WO2017091885A1/en not_active Ceased
- 2016-11-30 MX MX2018006527A patent/MX2018006527A/es unknown
- 2016-11-30 US US15/779,419 patent/US10889814B2/en active Active
- 2016-11-30 EP EP16869430.5A patent/EP3384028B1/en active Active
- 2016-11-30 CA CA3006827A patent/CA3006827A1/en active Pending
- 2016-11-30 CN CN201680069706.0A patent/CN108603194A/zh active Pending
- 2016-11-30 ES ES16869430T patent/ES2893294T3/es active Active
- 2016-11-30 AU AU2016363683A patent/AU2016363683B2/en active Active
- 2016-11-30 JP JP2018527863A patent/JP7039470B2/ja active Active
-
2020
- 2020-11-16 US US17/099,516 patent/US11466273B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2893294T3 (es) | 2022-02-08 |
| MX2018006527A (es) | 2018-11-29 |
| AU2016363683A1 (en) | 2018-07-12 |
| EP3384028A4 (en) | 2019-05-01 |
| WO2017091885A8 (en) | 2018-06-07 |
| US11466273B2 (en) | 2022-10-11 |
| CN108603194A (zh) | 2018-09-28 |
| AU2016363683B2 (en) | 2023-04-27 |
| EP3384028A1 (en) | 2018-10-10 |
| EP3384028B1 (en) | 2021-06-30 |
| US20190010492A1 (en) | 2019-01-10 |
| US10889814B2 (en) | 2021-01-12 |
| WO2017091885A1 (en) | 2017-06-08 |
| JP2019500334A (ja) | 2019-01-10 |
| US20210395733A1 (en) | 2021-12-23 |
| JP7039470B2 (ja) | 2022-03-22 |
| BR112018011045A2 (pt) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11466273B2 (en) | Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer | |
| US9764035B2 (en) | Methods and compositions for treating prostate cancer | |
| US9200285B2 (en) | Clusterin antisense therapy for treatment of cancer | |
| CN1703229B (zh) | 治疗前列腺和其他癌的组合物和其制备药物的用途 | |
| WO2018129622A1 (en) | Dual targeting antisense oligonucleotides for use as apoptotic inhibitors for the treatment of cancer | |
| TW201728334A (zh) | 用於治療癌症之組合物及方法 | |
| Keyvani et al. | Insight into RNA-based therapies for ovarian cancer | |
| CN118079005B (zh) | YAP抑制剂联合EGFR抑制剂和/或TGFβ1受体抑制剂在乳腺癌治疗中的应用 | |
| CN113908280A (zh) | Trim11抑制剂和二甲双胍的组合物在治疗肝细胞癌中的应用 | |
| CN120041444A (zh) | Brix1抑制剂及其在抗肿瘤中的用途 | |
| KR102574252B1 (ko) | 펩티드 핵산 복합체를 유효성분으로 함유하는 췌장암 예방 또는 치료용 조성물 | |
| BR112018011045B1 (pt) | Oligonucleotídeo anti-sentido (aso), uso do mesmo na fabricação de um medicamento para o tratamento de câncer e composição farmacêutica | |
| US20250205271A1 (en) | Micrornas for inhibiting the expression of trf2 in tumors | |
| CN116440275B (zh) | Mboat1在制备治疗癌症的试剂中用途 | |
| WO2018160699A1 (en) | Biomarkers for diagnosis, prediction and/or prognosis of pancreatic cancer and uses thereof | |
| US10835551B2 (en) | Double-stranded nucleic acid molecule, DNA, vector, cancer cell growth inhibitor, cancer cell migration inhibitor, and drug | |
| KR102212699B1 (ko) | 유방암 예방 또는 치료용 조성물 | |
| JP5976922B2 (ja) | 二本鎖核酸分子、ｄｎａ、ベクター、癌細胞増殖抑制剤、及び医薬 | |
| Liu et al. | Xiao Liu1, 2†, Zhengcong Cao1†, Nannan Liu3†, Guangxun Gao2, Mingrui Du4, Yingwen Wang1, Boyang Cheng1, Maorong Zhu1, Bo Jia2, Luxiang Pan1, Wangqian Zhang1, Yuran Jiang5, Wei He1, Linlin Xu2, Wei Zhang1, Qunxing An2*, Qingdong Guo2* and Jintao Gu1 | |
| CN108348539A (zh) | 用于治疗肿瘤的方法 | |
| CN120549959A (zh) | 一种靶向RAC1B的siRNA在制备治疗肺癌的药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211115 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241118 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241118 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241118 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED Effective date: 20250602 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250602 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT Effective date: 20251002 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251117 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |